SCHEMBL12236087

SCHEMBL12236087

CCCC[C@@H]1NC[C@H](C(=O)C2CC2)NC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 4/20 0.36
SIRT1 Q96EB6 4/20 0.36
SIRT3 Q9NTG7 4/20 0.36
ALDH1A1 P00352 3/20 0.35
HPGD P15428 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
PKM P14618 1/20 0.34
KMT2A Q03164 1/20 0.34
NAAA Q02083 4/20 0.34
CCR2 P41597 1/20 0.33
MMP1 P03956 1/20 0.32
MMP3 P08254 1/20 0.32
MMP9 P14780 1/20 0.32
POLB P06746 1/20 0.31
PRKCA P17252 1/20 0.31
USP2 O75604 1/20 0.31
GAA P10253 1/20 0.31
PRCP P42785 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13611032 1.00 SIRT2 (0.36) SIRT2SIRT1SIRT3ALDH1A1HPGD
SCHEMBL12236119 1.00 SIRT2 (0.36) SIRT2SIRT1SIRT3ALDH1A1HPGD
SCHEMBL12236110 1.00 SIRT2 (0.36) SIRT2SIRT1SIRT3ALDH1A1HPGD
SCHEMBL12629024 0.93 ALDH1A1 (0.40) SIRT2SIRT1SIRT3ALDH1A1HPGD
SCHEMBL10186994 0.84 ALDH1A1 (0.42) SIRT2SIRT1SIRT3ALDH1A1HPGD
SCHEMBL12572140 0.84 SIRT2 (0.40) SIRT2SIRT1SIRT3ALDH1A1HPGD
SCHEMBL12572105 0.84 SIRT2 (0.40) SIRT2SIRT1SIRT3ALDH1A1HPGD
SCHEMBL12572143 0.84 SIRT2 (0.40) SIRT2SIRT1SIRT3ALDH1A1HPGD
SCHEMBL13170335 0.84 SIRT2 (0.40) SIRT2SIRT1SIRT3ALDH1A1HPGD
SCHEMBL13435356 0.84 SIRT2 (0.40) SIRT2SIRT1SIRT3ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580747-B2 Cyclic natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2013-11-12 US disclosed
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates PALATIN TECHNOLOGIES, INC. (US) 2011-10-27 US disclosed
US-7964181-B2 Amino acid surrogates for peptidic constructs PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-7622440-B2 Cyclic natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2009-11-24 US disclosed
US-20070265206-A1 Cyclic Natriuretic Peptide Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-15 US disclosed
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates ARGLU1, QRFPR, ARG1 SIRT2 3293/4885SIRT1 3416/4885SIRT3 2986/4885
US-20070265206-A1 Cyclic Natriuretic Peptide Constructs NPR1, NPR3, NPPA SIRT2 4300/4885SIRT1 3674/4885SIRT3 4180/4885
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs ARGLU1, ARG1, QRFPR SIRT2 1440/4885SIRT1 1798/4885SIRT3 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.